National- and State-Level Pharmacy-Based Buprenorphine Dispensing, United States 2019-2021.
作者信息
Barham Chase L, Strahan Andrea E, Zhang Kun, Guy Gery P
机构信息
Oak Ridge Institute for Science and Education, Oak Ridge, TN, USA.
Centers for Disease Control and Prevention, National Center for Injury Prevention and Control, Atlanta, GA, USA.
出版信息
J Gen Intern Med. 2024 Aug;39(10):1951-1953. doi: 10.1007/s11606-024-08829-0. Epub 2024 May 28.
Abstract
摘要
相似文献
1
National- and State-Level Pharmacy-Based Buprenorphine Dispensing, United States 2019-2021.
J Gen Intern Med. 2024 Aug;39(10):1951-1953. doi: 10.1007/s11606-024-08829-0. Epub 2024 May 28.
2
Buprenorphine Dispensing after Elimination of the Waiver Requirement.
N Engl J Med. 2024 Apr 25;390(16):1530-1532. doi: 10.1056/NEJMc2312906.
3
Trends in Buprenorphine Treatment in the United States, 2009-2018.
JAMA. 2020 Jan 21;323(3):276-277. doi: 10.1001/jama.2019.18913.
4
Concentration of Patient Care Among Buprenorphine-Prescribing Clinicians in the US.
JAMA. 2021 Jun 1;325(21):2206-2208. doi: 10.1001/jama.2021.4469.
5
Authors' Response on "Rise in Neonatal Abstinence Syndrome Rate Is Associated with Rise in Buprenorphine Prescription Numbers".
South Med J. 2024 Aug;117(8):511-512. doi: 10.14423/SMJ.0000000000001712.
6
Why 24 State and Territorial Health Officials Support Buprenorphine Deregulation.
Am J Public Health. 2019 Dec;109(12):1678-1679. doi: 10.2105/AJPH.2019.305370.
7
Changes in Buprenorphine Prescribing in Community Health Centers.
JAMA Health Forum. 2024 Apr 5;5(4):e240634. doi: 10.1001/jamahealthforum.2024.0634.
8
Food and Drug Administration approval of sustained-release buprenorphine for treatment of opioid dependence: realizing its potential.
Addiction. 2017 Mar;112(3):386-387. doi: 10.1111/add.13539. Epub 2016 Aug 26.
9
Datapoints: regional variation in benzodiazepine prescribing for patients on opioid agonist therapy.
Psychiatr Serv. 2014 Jan 1;65(1):4. doi: 10.1176/appi.ps.650308.
10
A New Way Forward in the Emergency Department.
J Med Toxicol. 2019 Oct;15(4):220-222. doi: 10.1007/s13181-019-00718-x. Epub 2019 Jul 5.
引用本文的文献
1
Prescriber-Level Changes in Buprenorphine Dispensing in the USA Before and After Federal Policy Changes Aimed at Increasing Prescribing.
J Gen Intern Med. 2025 Jun 25. doi: 10.1007/s11606-025-09655-8.
2
Individuals Dispensed Buprenorphine in the United States Before and After Federal Policy Changes Aimed at Increasing Access.
J Addict Med. 2025 Feb 19. doi: 10.1097/ADM.0000000000001457.
本文引用的文献
1
Trends in Engagement With Opioid Use Disorder Treatment Among Medicaid Beneficiaries During the COVID-19 Pandemic.
JAMA Health Forum. 2022 Mar 11;3(3):e220093. doi: 10.1001/jamahealthforum.2022.0093. eCollection 2022 Mar.
2
Has the treatment gap for opioid use disorder narrowed in the U.S.?: A yearly assessment from 2010 to 2019".
Int J Drug Policy. 2022 Dec;110:103786. doi: 10.1016/j.drugpo.2022.103786. Epub 2022 Aug 4.
3
Trends in pharmacy-based dispensing of buprenorphine, extended-release naltrexone, and naloxone during the COVID-19 pandemic by age and sex - United States, March 2019 - December 2020.
Drug Alcohol Depend. 2022 Mar 1;232:109192. doi: 10.1016/j.drugalcdep.2021.109192. Epub 2021 Nov 26.
4
Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study.
Ann Intern Med. 2018 Aug 7;169(3):137-145. doi: 10.7326/M17-3107. Epub 2018 Jun 19.
Zotero 插件